GE HealthCare Technologies Inc. (GEHC)
GE HealthCare makes medical imaging systems, ultrasound, and patient-monitoring equipment.
GEHC vs IQV: how the two businesses compare
- Bigger business: GEHC, with $20.6B of yearly revenue, about 1.3× IQV's $16.3B.
- More profitable: GEHC keeps 10 cents of each sales dollar as profit, against 8 cents at IQV.
From each company's latest annual SEC filing. Fiscal years can end on different dates.
GE HealthCare Technologies (GEHC) is the larger business by reported revenue: $20.6B in its fiscal year ended Dec 2025, about 1.3× IQV's $16.3B (fiscal year ended Dec 2025). GEHC's net margin was 10.1% and IQV's 8.3%. The SEC classifies them differently (X-Ray Apparatus & Tubes & Related Irradiation Apparatus; Services-Commercial Physical & Biological Research); what connects them is shared exposure to the Artificial intelligence research theme, not a common industry.
Figures come from each company's own SEC filings. This page compares the businesses; it is not a price target or a verdict.
- Health Care
- Different
- Separate classifications
- December 31
- Same calendar
- Feb 17, 2026
GEHC vs IQV: quick comparison
| Company fact | GEHC | IQV |
|---|---|---|
| Company | GE HealthCare Technologies Inc. | IQVIA Holdings Inc. |
| Exchange | NASDAQ | NYSE |
| SEC industry | X-Ray Apparatus & Tubes & Related Irradiation Apparatus | Services-Commercial Physical & Biological Research |
| Fiscal year-end | December 31 | December 31 |
| Latest annual filing | 10-K · 2026-02-04 | 10-K · 2026-02-17 |
GEHC vs IQV: audited financials
- Scale: GEHC's $20.6B of revenue is about 1.3× IQV's $16.3B.
- Net margin: GEHC kept 10.1% of revenue as net income versus 8.3% at IQV.
- Periods: both fiscal years end on 2025-12-31, so these annual figures cover the same months.
| Metric | GEHC | IQV |
|---|---|---|
| Revenue | $20.6B2025-01-01 to 2025-12-31 · SEC filing | $16.3B2025-01-01 to 2025-12-31 · SEC filing |
| Net income | $2.1B2025-01-01 to 2025-12-31 · SEC filing | $1.4B2025-01-01 to 2025-12-31 · SEC filing |
| Operating cash flow | — | $2.7B2025-01-01 to 2025-12-31 · SEC filing |
| Diluted EPS | $4.552025-01-01 to 2025-12-31 · SEC filing | $7.842025-01-01 to 2025-12-31 · SEC filing |
| Net margin | 10.1%2025-01-01 to 2025-12-31 · SEC filing | 8.3%2025-01-01 to 2025-12-31 · SEC filing |
GEHC: FY ending 2025-12-31 · IQV: FY ending 2025-12-31. Figures as tagged in each issuer's SEC XBRL filing; fiscal calendars may not align.
Where GEHC and IQV overlap, and where they don't
Overlap
- Shared research theme: Artificial intelligence.
- Same fiscal calendar: both fiscal years end December 31.
Differences
- Different SEC industries: GEHC files as X-Ray Apparatus & Tubes & Related Irradiation Apparatus; IQV as Services-Commercial Physical & Biological Research.
Overlap is drawn from SEC classifications and Yield Theory research themes. It is not evidence that the companies sell to the same customers or compete product for product.
IQVIA Holdings Inc. (IQV)
IQVIA provides clinical-trial services and healthcare data analytics to drug developers.
What moves each company
Company-specific drivers maintained by Yield Theory. Use them to decide which filing deserves deeper work; they are not predictions.
What moves GEHC
We have not yet published a company-specific driver list for GEHC. The primary source is Item 1 (Business) and Item 1A (Risk Factors) of its 10-K filed 2026-02-04.
What moves IQV
We have not yet published a company-specific driver list for IQV. The primary source is Item 1 (Business) and Item 1A (Risk Factors) of its 10-K filed 2026-02-17.
The investment question
You now know GEHC reports about 1.3× IQV's revenue, and GEHC keeps more of each dollar as net income. Those are the facts. The investment question is what each share price already assumes about their exposure to artificial intelligence, and which evidence in the next filings would prove that assumption wrong.
Members-only research
What members are reading this month
- Issue 07: The Vote That Knocked Almost a Quarter off Data Center Stocks
Texas has frozen new data center approvals since the summer. The vote extends that freeze, but it cannot unplug campuses that already have power. We map who is exposed, test whether the sell-off overshot and say where the real risk sits.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchSEC filing comparison and disclosure evidence
Start with primary filings because fiscal calendars and accounting presentation can make superficially similar quarters incomparable. Both fiscal years end December 31, so annual reports line up, but check segment definitions before comparing growth or margins.
The current verified House and Senate snapshot contains 7 matched transaction rows for GEHC and 8 matched transaction rows for IQV. These delayed, range-based disclosures can identify a filing to inspect; they do not establish motive, conviction, or a real-time trading signal.
GEHC primary filings
IQV primary filings
What this comparison cannot tell you
This page does not contain licensed live prices, a valuation model, earnings estimates, portfolio constraints, or a forecast of future returns. SEC classifications can be broad, company descriptions can lag strategic change, and the latest annual filing may predate a material acquisition or divestiture. Read subsequent quarterly and current reports before making a decision.
A stronger business is not automatically the better stock. Starting valuation, expectations, capital structure, cyclicality, dilution, and the probability of each thesis determine the investment outcome. Use this comparison to frame the work, then verify the numbers in the linked filings and current company disclosures.
More comparisons involving GEHC or IQV
GEHC vs IQV FAQs
Are GEHC and IQV direct competitors?
Not necessarily. GE HealthCare Technologies files as X-Ray Apparatus & Tubes & Related Irradiation Apparatus and IQVIA as Services-Commercial Physical & Biological Research. The pair is compared because both map to the Artificial intelligence research theme, not because the filings show head-to-head competition.
Is GEHC or IQV the bigger company by revenue?
GE HealthCare Technologies (GEHC) is the larger business by reported revenue: $20.6B in its fiscal year ended Dec 2025, about 1.3× IQV's $16.3B (fiscal year ended Dec 2025). GEHC's net margin was 10.1% and IQV's 8.3%. The SEC classifies them differently (X-Ray Apparatus & Tubes & Related Irradiation Apparatus; Services-Commercial Physical & Biological Research); what connects them is shared exposure to the Artificial intelligence research theme, not a common industry. Each figure is the annual amount tagged in the company's own SEC XBRL filing; market value depends on live prices, which this page does not publish.
Which is better, GEHC or IQV?
There is no context-free winner. Compare the operating exposures, filing evidence, valuation, balance sheet, and risks against the specific thesis you are testing. This page deliberately does not turn a static profile into a buy or sell recommendation.
Does this GEHC vs IQV comparison include live prices?
No. Yield Theory does not republish unlicensed real-time market data. The financial figures on this page are the audited annual numbers GE HealthCare Technologies Inc. and IQVIA Holdings Inc. tagged in their SEC XBRL filings. Use a regulated broker or licensed quote provider for current prices and valuation multiples.
Where does the company information come from?
Company classifications, fiscal year-ends, and filing links come from the SEC EDGAR submissions API snapshot refreshed 2026-11-09. Business summaries and research themes are maintained by Yield Theory.
Data snapshot: SEC EDGAR submissions API, refreshed 2026-11-09. Independent educational research; not investment advice.
Which business differences matter to the investment thesis?
GEHC vs IQV compares reported results. The reports below show how we connect operating evidence to an investment thesis, its assumptions, catalysts, and risks. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included